WO2007113570A1 - Raman analysis of tissue - Google Patents
Raman analysis of tissue Download PDFInfo
- Publication number
- WO2007113570A1 WO2007113570A1 PCT/GB2007/001258 GB2007001258W WO2007113570A1 WO 2007113570 A1 WO2007113570 A1 WO 2007113570A1 GB 2007001258 W GB2007001258 W GB 2007001258W WO 2007113570 A1 WO2007113570 A1 WO 2007113570A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tissue
- breast
- raman
- composition
- radiation
- Prior art date
Links
- 238000001069 Raman spectroscopy Methods 0.000 title claims abstract description 87
- 238000004458 analytical method Methods 0.000 title description 6
- 210000000481 breast Anatomy 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 32
- 239000000203 mixture Substances 0.000 claims abstract description 31
- 208000004434 Calcinosis Diseases 0.000 claims abstract description 24
- 241001465754 Metazoa Species 0.000 claims abstract description 16
- 230000002308 calcification Effects 0.000 claims abstract description 16
- 230000003595 spectral effect Effects 0.000 claims abstract description 16
- 238000012624 non-invasive in vivo measurement Methods 0.000 claims abstract description 7
- 210000001519 tissue Anatomy 0.000 claims description 67
- 239000000523 sample Substances 0.000 claims description 56
- 238000005286 illumination Methods 0.000 claims description 32
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 26
- 238000005259 measurement Methods 0.000 claims description 21
- 230000005855 radiation Effects 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 15
- 210000000988 bone and bone Anatomy 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 claims description 4
- 210000000845 cartilage Anatomy 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- 210000000515 tooth Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 3
- 235000011010 calcium phosphates Nutrition 0.000 claims description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 230000005540 biological transmission Effects 0.000 abstract description 7
- 238000001514 detection method Methods 0.000 abstract description 6
- 238000001228 spectrum Methods 0.000 description 24
- 239000010410 layer Substances 0.000 description 21
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 19
- 230000003287 optical effect Effects 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 13
- 230000003902 lesion Effects 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 9
- 230000003211 malignant effect Effects 0.000 description 8
- 206010034203 Pectus Carinatum Diseases 0.000 description 7
- 239000000835 fiber Substances 0.000 description 7
- 230000000644 propagated effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001237 Raman spectrum Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000009607 mammography Methods 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000010183 spectrum analysis Methods 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- UGSQEBVMGSXVSH-UHFFFAOYSA-L calcium;oxalate;dihydrate Chemical compound O.O.[Ca+2].[O-]C(=O)C([O-])=O UGSQEBVMGSXVSH-UHFFFAOYSA-L 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 206010048782 Breast calcifications Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000000794 confocal Raman spectroscopy Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
- A61B5/0091—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for mammography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/43—Detecting, measuring or recording for evaluating the reproductive systems
- A61B5/4306—Detecting, measuring or recording for evaluating the reproductive systems for evaluating the female reproductive systems, e.g. gynaecological evaluations
- A61B5/4312—Breast evaluation or disorder diagnosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
- G01N2021/653—Coherent methods [CARS]
- G01N2021/656—Raman microprobe
Definitions
- the present invention relates to methods and apparatus for measurement of composition of a tissue within a human or animal subject, and in particular to such measurement made non invasively in vivo.
- the invention may be applied to the measurement of microcalcifications in tissue within a human breast, or to the measurement of bone, cartilage or other tissue composition in a finger, toe, hand or foot.
- Raman spectroscopy is the study of small shifts in the wavelength of photons, usually generated by a laser, as the photons undergo inelastic Raman scattering with molecules in various media. Interaction with different molecules gives rise to different spectral shifts, so that analysis of a Raman spectrum can be used to determine chemical composition of a sample.
- the very weak nature of the scattering makes Raman spectroscopy difficult to use in many circumstances, due to the Raman signal being swamped by fluorescence and other background signals .
- Raman spectroscopy has been used to analyse a wide variety of biological tissues. For example, Haka et al . "Identifying Microcalcifications in Benign and Malignant Breast Lesions by Probing Differences in Their Chemical Composition Using Raman Spectroscopy", Cancer Research 62, 2002 discusses the use of Raman spectroscopy to analyse the chemical composition of microcalcifications occurring in benign and malignant lesions in tissue samples removed from human breasts .
- WO03/073082A1 discloses the use of confocal Raman spectroscopy to make depth selective measurements of pH within skin.
- Figure 1 illustrates a scheme using Raman spectroscopy to detect, in vivo, characteristics of human or animal tissue, which is similar to that proposed in WO03/073082.
- a laser source 10 provides photons to confocal optics 12 which directs the photons into the surface tissue 14 of a subject.
- Raman scattering events 16 change the frequency of some of the photons, and some of the Raman scattered photons are backscattered to be collected by the confocal optics 12 and directed to a spectral analyser 18.
- An output of the spectral analyser is interpreted by a computer 20 to infer characteristics of the tissue within which the Raman scattering took place.
- a scheme such as that illustrated in figure 1 can be used to determined properties of tissue at or very close to the surface, for example, in the top few tens of micrometers .
- Raman scattering occurs deeper within the sample, the intensity of the incident radiation, and the number of Raman scattered photons backscattered to the sample surface drops off rapidly with depth, and quickly becomes swamped by fluorescence and other background signals.
- the collected photons can be time gated to exclude the time delayed fluorescence signal, as described in Morris et al .
- the present invention addresses these and other problems of the related prior art .
- the invention provides a method of probing within a part of a human or animal subject by directing probe light at a first surface of the part, and collecting scattered light from a second, opposing side of the part. Raman spectral features within the collected light are measured and used to determine characteristics of tissue within the part, such as the presence of particular substances.
- the invention is particularly advantageous because it allows non-invasive in vivo probing of parts of the human or animal body, and unlike prior art Raman techniques which are very heavily biased towards a thin surface layer, characteristics of an internal bulk of the part between the first and second sides are probed. Using the method, light which has been forward scattered through the body part in a transmission geometry, rather than being backscattered in a more conventional reflection geometry, is collected and analysed.
- the invention also provides corresponding apparatus, for example comprising illumination optics and collection optics arranged or directed at first and second opposing sides of a body part, a light source providing probe light to the illumination source, and a spectral analyser adapted to receive collected light from the collection optics and to determine one or more Raman spectral characteristics of the collected light.
- the spectral analyser could be provided, for example, by selected filters and suitable photon detection apparatus, or a conventional or fourier transform spectrograph.
- the invention also provides methods and apparatus for directing probe light at a first surface of a human or animal subject, collecting light at a second surface of the subject, and detecting a Raman spectral signal deriving from Raman scattering within an intervening tissue.
- the invention provides a method of non invasive in vivo measurement of composition of a tissue within a part of a human or animal subject, comprising: directing radiation into the part through a first exterior surface region of the part; collecting a portion of said radiation emerging at a second exterior surface region of the part following forward scattering through the part; detecting, in said collected radiation, characteristics of said radiation arising from Raman scattering by said tissue; and determining a measurement of composition of said tissue from said characteristics.
- the second surface region is spaced from said first surface region, preferably by an intervening volume of the tissue.
- at least some of said tissue is disposed between, and more preferably directly between the first and second surfaces.
- the second surface region may be on an opposite side of the part from the first surface region, at least during the steps of directing and collecting.
- the measurement of composition may be a measurement of composition of calcifications within said tissue, for example a measurement of at least one of a type I, calcium oxalate material and a type II, calcium phosphate material, for example calcium hydroxyapatite material .
- Such measurements are particularly suitable if the body part is a human or animal breast, in which case the breast may be compressed between opposing clamp or plate surfaces such that the first and second exterior surfaces of the breast are compressed towards each other by the clamp surfaces.
- the invention also provides a method of diagnosing a disease, such as a breast cancer condition, comprising determining said measurement of composition as set out above, and making a diagnosis of the disease based on said measurement of composition.
- the invention may be carried out on a variety of body parts such as a digit, limb, lip, ear, eyelid, tooth, tongue or nose, and the tissue may comprise one or more of tissues such as bone, cartilage, bone marrow, brain, nerves, lipids, blood, teeth and breast tissue.
- Figure 1 illustrates Raman probing of tissue using a backseattering geometry
- Figure 2 illustrates Raman probing of a body part using a forward scattering, transmission geometry
- Figure 3 shows a machine adapted for Raman probing of breast tissue in a clinical environment
- Figure 4 shows the structure of a sample idealised body part used in a Monte Carlo scattering model
- Figure 5 shows graphs of Raman light intensity either backscattered through the illuminated surface, or forward scattered through an opposing surface, plotted according to the depth of the Raman scattering event, and calculated using the model of figure 4;
- Figure 6 illustrates an experimental arrangement demonstrating the principals of the invention on a sample of chicken breast enclosing an optical cell containing calcified material similar to that found in breast lesions;
- Figure 7a shows spectra obtained with the cell empty, and containing either HAP or COM calcified material
- Figure 7b shows the HAP and COM spectra of figure 7a with the empty cell background subtracted
- Figure 7c shows spectra obtained in the same way as those of figure 7b but with chicken skin added to an outside surface of the sample
- Figure 8a shows spectra obtained by smearing the HAP or COM material onto an interior surface of the chicken breast in a thin layer instead of using an optical cell
- Figure 8b shows the HAP and COM spectra of figure 8a with the tissue only background spectrum subtracted.
- a part 30 of a human or animal body is shown in cross section disposed between illumination optics 32 and collection optics 34.
- a laser 36 provides a source of photons to the illumination optics 32, which directs the photons into the body part through a first external surface region 40 of the part.
- a small proportion of the photons undergo Raman scattering events 42 and are shifted in frequency by an amount dependent upon the tissue, and in particular the molecule within the tissue at which the scattering event takes place.
- Some of the Raman scattered photons pass out of the body part 30 through a second external surface region 44 of the part and are collected by the collection optics 34.
- the illumination optics and collection optics are disposed around the body part such that the collected photons have been forward scattered through the body part in a transmission geometry, rather than having been backscattered in a reflection geometry.
- the illumination and collection optics may be disposed on opposite sides of the body part when the method is carried out, preferably such that the tissue to be measured lies between the first and second surface regions.
- the photons collected by the collection optics are suitably analysed to determine characteristics of the Raman scattering taking place in the tissue.
- a spectral analyser 46 which could for example be a fourier transform spectrograph, or use one or more narrow pass filters, detects characteristics of the Raman photons.
- a computer 48 processes the data provided by the spectral analyser, for example to provide an indication of the chemical characteristics or composition of the tissue.
- the illumination and collection optics could take a variety of forms, such as bundles of optical fibres which can be manipulated for appropriate positioning adjacent to the first and second surface areas.
- the illumination and collection optics may be provided with automated means for scanning across the surfaces of the sample, and/or may be provided with distinct segments which can be selectively used to illuminate and/or collect photons from different parts of the part.
- the body part can be any of a variety of different body parts, and the illumination and collection optics may be adapted accordingly.
- the body part may be a digit or limb such as a finger, toe, foot, hand or ear, and the tissue measured could be bone, cartilage, joint fluid, blood or skin.
- FIG. 3 illustrates a machine 50 for carrying out the invention on human breasts.
- the machine is similar in many respects to X-ray machines familiar in the prior art for obtaining mammographic images used to detect breast cancer.
- a human breast is placed between two breast clamps or plates 52, typically made of or at least faced with a transparent plastic, which are then adjusted to compress the bulk of the breast to a thickness of about 2 cm.
- an X-ray source 54 is housed above the breast clamps 52, and an X-ray camera 56 or film is housed in the lower breast clamp.
- one of the breast clamps incorporates the illumination optics 32 of figure 2, and the other breast clamp incorporates the collection optics 34.
- the optics may be automatically driven to scan across the clamped breast, may be automatically driven or manually adjustable to be directed at a particular region of interest, or they may be of sufficient extent to cover a substantial portion of the clamped breast.
- the machine 50 may either include or not include X-ray facilities as described above. If X-ray facilities are included then X-ray image data may be used to direct operation of the Raman optics to study a particular part of a breast .
- the machine 50 preferably also includes means for spectral analysis of the collected Raman light, and computer apparatus for processing the results of the spectral analysis to present useful information to a clinician.
- the computer apparatus could be implemented to interpret the results of the spectral analysis in order to output data indicating the degree of presence of different chemical types of calcification in the probed breast tissue.
- Calcifications are found in may different biological tissues, forming both as natural products, e.g. in bones and teeth, and in soft tissues as a result of disease. Natural calcifications are present as a mineralization product in bone, and consist of the specific mineral hydroxyapatite .
- Pathological calcifications are associated with many medical conditions such as diabetes, breast cancer and crystals-associated osteoarthritis. The deposition of calcium crystals on cells induces detrimental cellular effects and speeds up the progression of the associated diseases.
- calcifications in mammographic images is a feature of particular diagnostic significance, as sometimes this may be the only marker of a malignant breast lesion.
- Mammography can detect small masses, areas of distortion, ill-defined densities and microcalcifications not detectable by physical examination. However, as this relies only on the morphology of the specimen, it has no definitive criteria for classifying benign and malignant calcifications. It has in fact been found that only 10-25% of mammographically detected lesions are found to be malignant upon needle biopsy.
- Microcalcifications can be divided into two types; type I, which consist of calcium oxalate dehydrate (COM), and type II deposits, which are composed of calcium phosphates, mainly calcium hydroxyapatite (HAP) .
- type I which consist of calcium oxalate dehydrate (COM)
- type II deposits which are composed of calcium phosphates, mainly calcium hydroxyapatite (HAP) .
- HAP calcium hydroxyapatite
- the methods and apparatus described herein may be used to measure the chemical make-up of lesions and calcifications non-invasively and in vivo, permitting a more simplistic decision for diagnosing breast lesions. This can be used to reduce patient trauma, time delay, and high medical costs associated with the biopsy of benign lesions. Numerical model
- a Monte Carlo model was used to simulate the transport of illumination photons and Raman photons scattering within a turbid medium such as the body part 30 of figure 2.
- the model was used to calculate the relative intensities of backscattered and forward scattered Raman photons as a function of their depth within the turbid medium. Briefly, both the elastically (illumination) and non-elastically (Raman) scattered photons were individually followed as they propagated through the medium in random walk-like fashion in three-dimensional space. A simplified assumption was made that in each step a photon propagated in a straight line over a distance t and thereafter its direction was fully randomised at the next scattering event.
- the propagation distance, t, over which the photon direction is randomised, can be crudely approximated as the transport length of the scattering medium (It) (Brenan C. and Hunter I., Journal of Raman Spectroscopy 27, p561, 1996) which is defined in a similar manner as the average distance photons must travel within the sample before deviating significantly from their original direction of propagation.
- Is (l-g)lt
- the modelled sample body part 60 is illustrated in figure 4.
- the sample body part was modelled as a uniform turbid medium apart from an intermediate-layer 66 having a different Raman signature to represent a tissue of interest, the intermediate layer having a thickness d2 with a top surface located at depth dl .
- the bulk sample medium was located at depths zl such that dl>zl>0 and d3>zl>(dl+d2) , and the intermediate layer of a different Raman signature at depths z2 such that dl+d2 ⁇ z2 ⁇ dl.
- the parameters d2 and d3 were fixed at 0.5 mm and 4 mm respectively, and dl was varied from 0 to 3.5 mm to represent different depths of the interlayer 66 within the bulk of the sample 60.
- the model assumed that all the illumination photons were first placed at a depth equal to the transport length It and symmetrically distributed around the origin of the co-ordinate system x,y.
- the beam radius of the incident light r was 3 mm and the beam was given a uniform x top-hat' intensity profile with all the photons having equal probability of being injected into the sample at any point within its cross-section.
- the Raman light was collected firstly at the top sample surface 62 from the illumination area of the incident light, and separately on the opposite side of the sample 64 symmetrically around the projection axis of the top collection/laser illumination area.
- the laser beam photons were propagated through the medium by translating each individual photon in a random direction by a step t. At each step there was a given probability that the photon would be converted to a Raman photon. The absorption of photons was assumed to be insignificant in this simulation.
- This parameter is expressed as optical density for the conversion of laser beam photons to Raman light. That is, for example, an optical density (OD) of 1 or 2 per 1 mm corresponds to the 10-fold or 100-fold decrease of the number of illumination photons through conversion to Raman photons, respectively, passing through an overall propagation distance of 1 mm.
- the optical density accounting for the conversion of illumination photons into Raman photons was set to 0.01 per millimetre.
- the number of Raman photons originating in the intermediate layer 66 and collected as backscattered photons at the upper surface 62, and transmitted photons at the lower surface 64, are shown in figure 5.
- the dependence of the intensity of transmitted Raman photons exhibits only a weak dependence on the position of the intermediate layer within the sample.
- the corresponding Raman signal varies only by a factor of about 2.
- the absolute intensity of the Raman signal from the intermediate layer is only about 20-times lower than that of the bulk medium making detection relatively straightforward. Therefore the transmission geometry clearly provides a more representative sampling of the bulk of the body part interior than the conventional backscattering geometry, while permitting a satisfactory sensitivity.
- the model also reveals that an increase in sample body part thickness from 1 mm to
- 4 mm results in a 58% increase of the Raman signal detected in the backscattering geometry. In simplistic terms, this could be wrongly interpreted as extra Raman photons (amounting to 37 % of the overall Raman signal observed for 4 mm thick body part) being produced in the extra 3 mm thickness added to the top 1 mm sample layer.
- the model of a 4 mm-thick body part indicates that 88 % of Raman signal originates in the top 1 mm layer and only 12 % originates within the remaining 3 mm of body part thickness.
- the extra 3 mm of material not only contributes with extra production of Raman photons but also reduces the loss of Raman photons originated within the 1 mm-layer at the lower surface 64.
- a laser 78 was used to generate an illumination beam directed at a first surface region 80 of the sample using illumination optics, and light scattered through the whole thickness of the sample including the optical cell 74 and two layers of chicken breast 72 to a second surface region 82 was gathered using collection optics. The Raman components of the collected light were then analysed to determine the degree to which the material in the optical cell could be detected and identified.
- the illumination beam was generated using a temperature stabilised diode laser 78 suitable for Raman spectroscopy and operating at 827 nm (Micro Laser Systems, Inc, L4 83OS- 115-TE) .
- the laser power at the first surface region was about 60 mW and the laser spot diameter at the first surface region was about 4 mm.
- the beam was spectrally purified by removing any residual amplified spontaneous emission components from its spectrum using two 830 nm Semrock (RTM) bandpass filters (84) . These were slightly tilted to optimise throughput at the 827 nm laser wavelength.
- the illumination optics were provided by a fibre optic probe 86 at which a bundle of seven core optical fibres and 26 outer ring fibres terminated. This probe was of the same construction as the probe used in the collection optics, described in more detail below.
- the light scattered through the sample to the second surface region 82 was collected using the following collection optics . Light emerging from the region was gathered by a 50 mm diameter lens 90 with a focal length of 60 mm.
- the gathered light was collimated and passed through a 50 mm diameter holographic notch filter 92 (830 nm, Kaiser Optical Systems, Inc) to suppress the elastically scattered component of light corresponding to the original laser frequency.
- the filter was also slightly tilted to optimise the suppression for the 827 nm elastic scatter.
- a second lens 94 identical to the first, was then used to image, with magnification 1:1, the sample interaction zone onto the front face of a fibre probe 96.
- the laser incident spot at the first surface region was positioned in such a way so that it coincided with the centre of the probe axis as projected through the imaging system onto the sample.
- a 25 mm diameter holographic notch filter, 830 nm, Kaiser Optical Systems, Inc. (98) and an edge filter, 830 nm, Semrock (99) were used just before the probe 96 to suppress any residual elastically scattered light that passed through the first holographic filter 92.
- the fibre probe 96 was comprised of 7 fibres placed tightly packed at the centre of the probe and 26 fibres distributed on a ring of 3 mm radius.
- the fibres were made of silica with a core diameter of 200 ⁇ m, cladding diameter of 230 ⁇ m and numerical aperture of 0.37. Sleeves were stripped on both ends for tighter packing of the fibres.
- the bundle was custom made by C Technologies Inc.
- the Raman spectra were collected using a deep depletion cooled CCD camera 102 by binning the signal from both sets of fibres into a single spectrum (full vertical chip binning) .
- the Raman spectra are not corrected for the variation of detection system sensitivity across the active spectral range.
- Figure 7a shows spectra measured using the above arrangement when the optical cell was empty (110) , when the optical cell was filled with HAP powder (112) and when the optical cell was filled with COM powder (114) . These spectra are drawn with reference to the scale on the right hand axis, with additional arbitrary offsets to separate the spectra in the vertical direction.
- Figure 7b is a presentation of the HAP (120) and COM (122) spectra of figure 7a with the tissue-only spectrum (110) subtracted therefrom, again with pure HAP and COM spectra shown for reference purposes .
- the experiment was repeated with the addition of a layer of chicken skin to one surface of the sample, and figure 7c, which is otherwise the same as figure 7b, shows the results of this experiment with the background subtracted HAP spectrum as 124 and the background subtracted COM spectrum as 126.
- the sensitivity and penetration depth of the technique can be improved further by increasing the power of the incident light beam and the efficiency of the collection system.
- the incident light beam and consequently the first surface region may be enlarged, for example to a diameter of several centimetres, allowing incident light beam powers approaching 1 Watt to be used safely.
- the collection optics may be similarly scaled to collect as much of the transmitted light as possible, for example using imaging optics, a large fibre bundle, or both to cover an large second surface region.
- the illumination and collection optics can take a variety of forms.
- the illumination light may be projected onto the first surface region from wide range of distances, depending on the detailed circumstances of the application, using imaging optics or optical fibres.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007232354A AU2007232354A1 (en) | 2006-04-05 | 2007-04-05 | Raman analysis of tissue |
CN2007800207096A CN101460091B (en) | 2006-04-05 | 2007-04-05 | Raman analysis of tissue |
CA002648228A CA2648228A1 (en) | 2006-04-05 | 2007-04-05 | Raman analysis of tissue |
EP07732306.1A EP2010042B1 (en) | 2006-04-05 | 2007-04-05 | Raman analysis of tissue |
JP2009503653A JP2009538156A (en) | 2006-04-05 | 2007-04-05 | Raman analysis of the organization |
US12/225,928 US8259902B2 (en) | 2006-04-05 | 2007-04-05 | Raman analysis of tissue and/or calcifications |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0606891.0A GB0606891D0 (en) | 2006-04-05 | 2006-04-05 | Raman Analysis Of Pharmaceutical Tablets |
GB0606891.0 | 2006-04-05 | ||
GBGB0616376.0A GB0616376D0 (en) | 2006-04-05 | 2006-08-17 | Raman analysis of tissue |
GB0616376.0 | 2006-08-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007113570A1 true WO2007113570A1 (en) | 2007-10-11 |
Family
ID=38283317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2007/001258 WO2007113570A1 (en) | 2006-04-05 | 2007-04-05 | Raman analysis of tissue |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007113570A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101773396A (en) * | 2010-02-12 | 2010-07-14 | 杭州吴越电子有限公司 | DDR (digital data receiver) breast X-ray machine |
US8085396B2 (en) | 2006-04-05 | 2011-12-27 | The Science And Technology Facilities Council | Raman analysis |
JP2014025943A (en) * | 2013-09-06 | 2014-02-06 | Canon Inc | Detection device |
US8688199B2 (en) | 2008-05-14 | 2014-04-01 | Ucl Business Plc | Tissue assessment |
CN105455782A (en) * | 2015-12-17 | 2016-04-06 | 李婷 | Non-invasive spine marrow lesion detector |
CN111433863A (en) * | 2017-11-30 | 2020-07-17 | 株式会社新世 | Health state management system, method for controlling health state management system, and program |
US11406267B2 (en) | 2017-01-20 | 2022-08-09 | Olympus Corporation | Cartilage-tissue analysis device |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5261410A (en) * | 1991-02-07 | 1993-11-16 | Alfano Robert R | Method for determining if a tissue is a malignant tumor tissue, a benign tumor tissue, or a normal or benign tissue using Raman spectroscopy |
US5349961A (en) * | 1983-10-14 | 1994-09-27 | Somanetics Corporation | Method and apparatus for in vivo optical spectroscopic examination |
WO1996026431A1 (en) * | 1995-02-21 | 1996-08-29 | Massachusetts Institute Of Technology | Optical imaging using time gated scattered light |
US20030004419A1 (en) * | 2001-06-28 | 2003-01-02 | Treado Patrick J. | Method for Raman chemical imaging of endogenous chemicals to reveal tissue lesion boundaries in tissue |
US20050283058A1 (en) * | 2004-06-09 | 2005-12-22 | Choo-Smith Lin-P Ing | Detection and monitoring of changes in mineralized tissues or calcified deposits by optical coherence tomography and Raman spectroscopy |
-
2007
- 2007-04-05 WO PCT/GB2007/001258 patent/WO2007113570A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5349961A (en) * | 1983-10-14 | 1994-09-27 | Somanetics Corporation | Method and apparatus for in vivo optical spectroscopic examination |
US5261410A (en) * | 1991-02-07 | 1993-11-16 | Alfano Robert R | Method for determining if a tissue is a malignant tumor tissue, a benign tumor tissue, or a normal or benign tissue using Raman spectroscopy |
WO1996026431A1 (en) * | 1995-02-21 | 1996-08-29 | Massachusetts Institute Of Technology | Optical imaging using time gated scattered light |
US20030004419A1 (en) * | 2001-06-28 | 2003-01-02 | Treado Patrick J. | Method for Raman chemical imaging of endogenous chemicals to reveal tissue lesion boundaries in tissue |
US20050283058A1 (en) * | 2004-06-09 | 2005-12-22 | Choo-Smith Lin-P Ing | Detection and monitoring of changes in mineralized tissues or calcified deposits by optical coherence tomography and Raman spectroscopy |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8085396B2 (en) | 2006-04-05 | 2011-12-27 | The Science And Technology Facilities Council | Raman analysis |
US8688199B2 (en) | 2008-05-14 | 2014-04-01 | Ucl Business Plc | Tissue assessment |
CN101773396A (en) * | 2010-02-12 | 2010-07-14 | 杭州吴越电子有限公司 | DDR (digital data receiver) breast X-ray machine |
CN101773396B (en) * | 2010-02-12 | 2013-06-05 | 杭州吴越电子有限公司 | DDR (digital data receiver) breast X-ray machine |
JP2014025943A (en) * | 2013-09-06 | 2014-02-06 | Canon Inc | Detection device |
CN105455782A (en) * | 2015-12-17 | 2016-04-06 | 李婷 | Non-invasive spine marrow lesion detector |
US11406267B2 (en) | 2017-01-20 | 2022-08-09 | Olympus Corporation | Cartilage-tissue analysis device |
CN111433863A (en) * | 2017-11-30 | 2020-07-17 | 株式会社新世 | Health state management system, method for controlling health state management system, and program |
CN111433863B (en) * | 2017-11-30 | 2024-03-29 | 株式会社新世 | Health state management system, control method for health state management system, and storage medium |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2010042B1 (en) | Raman analysis of tissue | |
Matousek et al. | Recent advances in the development of Raman spectroscopy for deep non‐invasive medical diagnosis | |
Taroni et al. | Time-resolved optical mammography between 637 and 985 nm: clinical study on the detection and identification of breast lesions | |
Kallaway et al. | Advances in the clinical application of Raman spectroscopy for cancer diagnostics | |
Grosenick et al. | Time-domain scanning optical mammography: I. Recording and assessment of mammograms of 154 patients | |
US6954667B2 (en) | Method for Raman chemical imaging and characterization of calcification in tissue | |
CN104159500B (en) | Device for the characteristic for determining tissue | |
Esmonde-White et al. | Fiber-optic Raman spectroscopy of joint tissues | |
US20070073156A1 (en) | Combined visual-optic and passive infra-red technologies and the corresponding systems for detection and identification of skin cancer precursors, nevi and tumors for early diagnosis | |
EP2875771A1 (en) | Measurement/display method and measurement/display device for dental plaque, gum and alveolar bone | |
CN104067313B (en) | Imaging device | |
EP1845837A1 (en) | Method and apparatus for measuring cancerous changes from reflectance spectral measurements obtained during endoscopic imaging | |
WO2007113570A1 (en) | Raman analysis of tissue | |
CN101115986A (en) | Raman spectroscopic analysis of subsurface structures and liquids | |
CA2467407C (en) | Optical transillumination and reflectance spectroscopy to quantify disease risk | |
Rinneberg et al. | Scanning time-domain optical mammography: detection and characterization of breast tumors in vivo | |
Ghita et al. | Exploring the effect of laser excitation wavelength on signal recovery with deep tissue transmission Raman spectroscopy | |
Anwar et al. | Optical diagnostic of breast cancer using Raman, polarimetric and fluorescence spectroscopy | |
US20060089553A1 (en) | Method and apparatus for investigating histology of epithelial tissue | |
Dev et al. | Application of terahertz imaging in biological sciences, a review | |
WO2012127378A1 (en) | An apparatus for optical analysis of an associated tissue sample | |
Abd Ghani et al. | VIS–NIR spectral signature and quantitative analysis of HeLa and DU145 cell line | |
KR20240039441A (en) | OCT System for Analyzing Brain Tumor Margin using Near Infrared Light Source | |
Okagbare et al. | Transcutaneous Raman spectroscopy for assessing progress of bone-graft incorporation in bone reconstruction and repair | |
Taroni et al. | Multi-wavelength time domain optical mammography |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780020709.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07732306 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2648228 Country of ref document: CA Ref document number: 12225928 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009503653 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007232354 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8918/DELNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007732306 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2007232354 Country of ref document: AU Date of ref document: 20070405 Kind code of ref document: A |